AGI-1067: Began Phase IIb study

AtheroGenics Inc. (AGIX), Atlanta, Ga. Product: AGI-1067 Business: Cardiovascular Therapeutic category: Cell adhesion Target: Adhesion molecules Description: Oral small molecule that blocks expression...